News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase II
Alnylam (ALNY) Initiates Phase II Clinical Study Of Cemdisiran (ALN-CC5) In Patients With Atypical Hemolytic-Uremic Syndrome (aHUS) 9/26/2017
DFB Soria Gives Update On Enrollment In Phase 2 Clinical Trial Of SOR007 (Nanoparticle Paclitaxel) Ointment For Actinic Keratosis (AK) 9/26/2017
Medivir (MVRBF) Announces Positive Topline Results From Phase IIa Osteoarthritis Study, Showing Disease-Modifying Benefit Of MIV-711 On Joint Structure 9/26/2017
Neurana Pharma Completes Enrollment In Study Designed To Confirm The Non-Sedative Effects Of Tolperisone, A Novel Skeletal Muscle Relaxant 9/26/2017
Akebia (AKBA) Hits A New High As Kidney Disease Drug Meets Mid-Stage Trial Goals 9/26/2017
Why Drugmakers Do Interim Clinical Trials 9/26/2017
BioLineRx Announces Initiation Of Phase Ib/II Trial For BL-8040 In AML Under Immunotherapy Collaboration 9/26/2017
Capricor (CAPR) Advances Clinical Development Program In Duchenne Muscular Dystrophy With Naming Of Principal Investigator 9/26/2017
Argenx Launches Phase II Proof-Of-Concept Clinical Trial Of ARGX-113 For The Treatment Of Pemphigus Vulgaris 9/26/2017
Aserias Biotherapeutics Receives Regulatory Clearance To Initiate Clinical Study Of AST-VAC2 In Subjects With Early And Late Stage Non-Small Cell Lung Cancer 9/26/2017
BioLineRx Announces Initiation Of Phase Ib/II Trial For BL-8040 In AML Under Immunotherapy Collaboration 9/26/2017
3 Biotechs With Make-or-Break Trial Results, FDA Meetings Coming Soon 9/25/2017
AMO Pharma Reports Update On Positive Interim Analysis For The First Cohort Of Phase IIa Congenital Myotonic Dystrophy Study 9/25/2017
ProMetic Life Sci (PFSCF.PK) Receives FDA Clearance Of Its IND To Initiate Pivotal PBI-4050 Phase II/III Trial In Patients With Idiopathic Pulmonary Fibrosis 9/25/2017
Arbutus Biopharma (ABUS) Announces Topline Results For ARB-1467 Phase II Cohort 4 9/25/2017
Biophytis Filed IND Application For Approval By FDA Of SARA-INT Phase IIb Study Of Sarconeos In Sarcopenia 9/25/2017
Gelesis100 Achieves Significant Weight Loss With Excellent Safety Profile In Pivotal Study 9/25/2017
American Society For Radiation Oncology Release: Adding Radiation To Chemotherapy May Dramatically Improve Survival For Advanced-Stage NSCLC Patients 9/25/2017
American Society For Radiation Oncology Release: Long-Term Survival Rates More Than Double Previous Estimates For Locally Advanced Lung Cancer 9/25/2017
Allergan (AGN) Release: New Data From CENTAUR Phase IIb Clinical Study Supports Continued Development Of Cenicriviroc (CVC) In Ongoing Phase III AURORA Trial 9/22/2017
Starpharma Release: DEP Docetaxel Positive Phase I Results; Phase II Commences 9/22/2017
Abivax (ABVX.PA) Receives French Regulatory Approval To Begin Clinical Trial Of ABX464 In Ulcerative Colitis 9/22/2017
Patara Pharma's Phase II Study Results For Treatment Of Persistent Cough In IPF Patients Published In The Lancet Respiratory Medicine 9/21/2017
Audentes (BOLD) Announces Dosing Of First Patient In ASPIRO, A Phase I/II Clinical Trial Of AT132 For The Treatment Of X-Linked Myotubular Myopathy 9/21/2017
Paratek (PRTK) Release: Omadacycline Receives Qualified Infectious Disease Product Designation From FDA For An Additional Indication In Uncomplicated Urinary Tract Infection 9/21/2017
GrayBug Initiates Phase 1/2 Trial Of GB-102 For Wet Age-Related Macular Degeneration 9/21/2017
Bavarian Nordic (BAVA.CO) Provides Update On Its Universal RSV Vaccine 9/21/2017
EM Imaging Commences Phase II European Cancer Trial 9/20/2017
Sun Pharma (SUNPHARMA.NS) Odomzo (Sonidegib) New Label Approval Shows Sustained Duration Of Response Of 26 Months In Treatment Of Locally Advanced Basal Cell Carcinoma 9/20/2017
BioCardia Announces Publication Of 12-Month Results From Phase II TRIDENT Clinical Trial That Shows Positive Safety Profile For Allogeneic Bone Marrow Stem Cells Delivered With Helix Transendocardial Delivery System 9/20/2017
The Parker Institute For Cancer Immunotherapy And The Cancer Research Institute Announce First Patients Treated In Pancreatic Cancer Clinical Trial Combining Immunotherapy And Chemotherapy 9/20/2017
Cavion Announces First Patient Enrolled In Its Multi-Center Phase II Clinical Trial In Essential Tremor 9/20/2017
International Stem Cell Corporation To Move Forward With Traumatic Brain Injury Phase II Clinical Trial 9/20/2017
Altimmune Announces its Phase II Flu Vaccine Trial With NasoVAX Open For Enrollment 9/20/2017
Argenx Reaches 50% Enrollment In Phase II Clinical Trial Of ARGX-113 In Immune Thrombocytopenia 9/20/2017
Bone Therapeutics: Announces All Patients Meet Primary Endpoint In ALLOB Phase I/IIA Delayed-Union Study Interim Analysis 9/20/2017
Athera Biotechnologies Concludes Follow-Up Visits In Multiple Dosing Trial With Its Immunovascular Antibody 9/19/2017
Medical Prognosis Institute - Liplacis Phase II Recruitment Ongoing In DRP Screened Breast Cancer Patients: Relevant Clinical Benefits In 3 Out Of 5 Treated Patients 9/19/2017
Aclaris (ACRS) Announces Publication Of Data From Phase II Clinical Trial Of A-101 Topical Solution For Treatment Of Facial Seborrheic Keratosis 9/19/2017
MyoKardia Presents Additional Positive Data From Phase II PIONEER-HCM Study Of Mavacamten (Formerly MYK-461) At The Heart Failure Society Of America’s 21st Annual Scientific Meeting 9/19/2017
Ophthotech (OPHT) Provides Update On Zimura Complement Programs For Treatment Of Eye Diseases 9/19/2017
ProMetic Life Sci (PFSCF.PK) Reports Positive Clinical Data From Ongoing PBI-4050 Study In Alström Syndrome Patients 9/19/2017
Madrigal Announces Positive Outcome From Pre-Planned DSMB Safety Review And Completion Of Enrollment Of Phase II Study Of MGL-3196 In Patients With Heterozygous Familial Hypercholesterolemia 9/19/2017
Imago Biosciences Doses First Patients In Phase I/II Study Of IMG-7289 In Myelofibrosis 9/19/2017
Amylyx Receives FDA Orphan Drug Designation For AMX0035 For The Treatment Of Amyotrophic Lateral Sclerosis 9/19/2017
MiMedx Files With The FDA To Initiate The Company's Investigational New Drug Phase II Clinical Trial For Osteoarthritis Of The Knee 9/19/2017
Immuron Highlights Recent Milestones In Quest To Effectively Treat Multiple Forms Of Fatty Liver Diseases That Impact Millions 9/19/2017
MediciNova, Inc. Announces The Completion Of Enrollment In The Phase II Clinical Trial Of MN-166 (Ibudilast) In Methamphetamine Dependence 9/19/2017
Oncolytics Biotech (ONC.TO) Announces Successful End-Of-Phase II Meeting With FDA For REOLYSIN In Metastatic Breast Cancer 9/18/2017
Abivax (ABVX.PA): First Patient Dosed In Three-Month Cohort Of Phase 2a Study Of Oral ABX464 In HIV-Suppressed Patients 9/18/2017
Menlo Therapeutics Release: Serlopitant Pruritus Reduction Results From Two Phase II Studies Presented At The 26th European Academy Of Dermatology And Venereology 9/18/2017
Formula Pharmaceuticals, Inc. Announces Initiation Of The First Clinical Trial For Allogeneic CIK-CAR Cancer Immunotherapy 9/18/2017
Principia Biopharma Presents Late-Breaking Interim Phase II Data Of PRN1008 In Pemphigus At European Academy Of Dermatology And Venereology Meeting 9/18/2017
Principia Biopharma Presents Late-Breaking Interim Phase II Data Of PRN1008 In Pemphigus At European Academy Of Dermatology And Venereology Meeting 9/18/2017
Ability Pharma Announces EMA-Orphan Drug Designation For ABTL0812 In Pancreatic Cancer 9/18/2017
Autolus Announces First-Dose Cohort Completed In APRIL Study Of AUTO2: A Phase I/II Study In Patients With Multiple Myeloma 9/18/2017
Autolus Announces Initiation Of The Amelia And Alexander Studies For Auto3: Phase I/II Studies In Paediatric ALL and DLBCL 9/18/2017
Who Will Win The Kidney Cancer Battle Between Bristol-Myers Squibb (BMY) And Exelixis (EXEL)? 9/15/2017
Biohaven (BHVN) And Alzheimer's Disease Cooperative Study (ADCS) Announce Phase II Clinical Trial Collaboration Evaluating Glutamate Modulating Agent Trigriluzole In Patients With Mild-To-Moderate Alzheimer's Disease 9/15/2017
Catabasis (CATB) To Present Results From The Open-Label Extension Of The Movedmd Phase II Trial Of Edasalonexent In Duchenne Muscular Dystrophy In A Late Breaking Session Of The World Muscle Society 9/15/2017
Soleno Therapeutics Presents Updated Safety And Efficacy Data From Clinical Trial Of DCCR For Treatment Of Prader-Willi Syndrome 9/15/2017
Motif BioSciences, Inc. Announces Iclaprim Granted Orphan Drug Designation By FDA For Treatment Of Staphylococcus Aureus Lung Infections In Patients With Cystic Fibrosis 9/15/2017
Phrixus Pharmaceuticals Announces Phase II Clinical Trial Of Poloxamer 188 NF In Non-Ambulatory Patients With Duchenne Muscular Dystrophy 9/14/2017
Vanda (VNDA) Drops On Mixed Dermatitis Drug Trial Data 9/14/2017
Innovation Pharma (Formerly known as Cellceutix) (CTIX) Opens New Clinical Site For Novel P53 Drug Candidate In Phase II Ovarian Cancer Trial 9/14/2017
Eli Lilly (LLY) Release: Baricitinib Meets Primary Endpoint In Phase II Study Of Patients With Moderate-To-Severe Atopic Dermatitis 9/14/2017
Medivir (MVRBF) Release: Data Monitoring Committee Gives 'Go Ahead' In The MIV-711 Osteoarthritis Extension Study 9/14/2017
SELLAS Life Sci' Galinpepimut-S Induces Specific, Robust And Durable Immune Responses In Patients With High-Risk Multiple Myeloma - Correlated With Clinical Benefit 9/14/2017
Bone Therapeutics : Reports Strong Interim Results From ALLOB Phase IIA Spinal Fusion Study 9/14/2017
GTX Corp Announces Positive Results From Enobosarm Phase II Proof-Of-Concept Clinical Trial In Women With Stress Urinary Incontinence 9/13/2017
Iovance Biotherapeutics Announces Approval Of First Clinical Trial Application By Competent Authority In Netherlands For A Phase II Trial Of LN-145 For The Treatment Of Patients With Cervical Cancer 9/13/2017
PharmaMar Release: New Positive Data On PM1183 Sees A Response Rate Of 36% As Single Agent In Patients With Advanced And Relapsed Small-Cell Lung Cancer 9/13/2017
FibroGen (FGEN) Presents Latest Data From Phase IIb Study Of Pamrevlumab In Idiopathic Pulmonary Fibrosis At European Respiratory Society (ERS) International Congress 2017 9/13/2017
Zafgen (ZFGN) Initiates Phase II Clinical Trial For ZGN-1061 In Patients With Type 2 Diabetes 9/13/2017
Bonti Announces Presentation Of EB-001 Clinical Study Results At American Society for Dermatologic Surgery Annual Meeting 9/13/2017
Abivax (ABVX.PA) Presents Full ABX464 Positive Phase IIA Clinical HIV Data At The HIV Cure And Reservoir Symposium 9/13/2017
Oncoceutics Begins ONC201 Endometrial Cancer Trial; Receives NIH Grant 9/13/2017
Eisai Company (ESALY.PK) Presents Results Of Phase Ib/II Clinical Study Of Lenvima (Lenvatinib) In Combination With Pembrolizumab For Renal Cell Carcinoma In Oral Session At ESMO 2017 Congress 9/13/2017
Shire (SHPG) Receives FDA Fast Track Designation For SHP607 For The Prevention Of Chronic Lung Disease In Extremely Premature Infants 9/13/2017
Vertex (VRTX)’s Terminated Phase II CF Trial Was Planned 9/13/2017
Aldeyra (ALDX) Announces Positive Results From Dry Eye Disease Phase IIa Clinical Trial 9/12/2017
Nektar (NKTR) Initiates PROPEL Clinical Study To Evaluate Combination Of NKTR-214, A CD122-Biased Agonist, With TECENTRIQ (Atezolizumab) Or KEYTRUDA (Pembrolizumab) 9/12/2017
Cytokinetics (CYTK) Announces Additional Results From COSMIC-HF To Be Presented At The HFSA 21st Annual Scientific Meeting 9/12/2017
Novo Nordisk A/S (NVO) Release: More People Treated With Once-Weekly Semaglutide Achieved Reductions In Both Glucose And Weight Vs. Comparator Treatments 9/12/2017
Saniona Presents Tesomet Phase II Data At The EASD Congress 9/12/2017
DiaMedica Announces The Initiation Of Phase II Trial Evaluating DM199 (Recombinant Human KLK1) In Patients With Acute Ischemic Stroke 9/11/2017
Curis (CRIS) And Aurigene Discovery Technologies Limited Announce CA-170 Program Update Following Data Presented At ESMO 2017 9/11/2017
Immunomedics (IMMU) Presents Interim Phase II Results With Sacituzumab Govitecan (IMMU-132) In Patients With Pretreated Metastatic Urothelial Cancer 9/11/2017
Rexahn Pharmaceuticals, Inc. (RNN) Presents Preliminary Efficacy Data From The Ongoing Phase IIa Clinical Trial Of RX-3117 In Advanced Bladder Cancer At The 2017 European Society For Medical Oncology (ESMO) Congress 9/11/2017
X4 Pharma Release: Initial Clinical Trial Data For Combination Of X4P-001-IO And Inlyta (Axitinib) Demonstrate Encouraging Disease Control Rates And Durable Clinical Responses In Patients With Clear Cell Renal Cell Carcinoma (ccRCC) 9/11/2017
Phosplatin Therapeutics Announces Collaboration With Pfizer (PFE) And Merck KGaA (MKGAF.PK), Darmstadt, Germany To Evaluate Combination Of PT-112 And Avelumab In Phase I / II Studies 9/11/2017
Eisai Inc. (ESALF.PK) Release: Combination Of Lenvatinib And Pembrolizumab Results In Notable Response Rates For Patients With Advanced Renal Cell Carcinoma Based On Interim Analysis Of Ongoing Phase Ib/II Trial 9/11/2017
IRX Therapeutics Presents Positive IRX-2 Phase IIa Head And Neck Squamous Cell Carcinoma Clinical Results At The European Society For Medical Oncology Annual Congress 2017 9/11/2017
Syros Pharma Presents PK And PD Data At ESMO For SY-1425, Its First-In-Class Selective Rara Agonist, In Genomically Defined AML And MDS Patients 9/11/2017
Berg Presents Key Clinical Data At ESMO 2017 On BPM 31510 For Advanced Pancreatic Cancer Patients And BPM 31543 For Preventing Hair-Loss In Patients Treated With Chemotherapy 9/11/2017
Viking Therapeutics (VKTX) Announces Results Of Gene Expression Analysis From In Vivo Study Of VK2809 In Non-Alcoholic Steatohepatitis (NASH) 9/11/2017
Daiichi Sankyo Presents New Data For DS-8201 In Multiple HER2-Expressing Solid Tumors At European Society For Medical Oncology (ESMO) 2017 Congress 9/11/2017
Ipsen (IPN.PA) And Exelixis (EXEL) Announce Results From Phase II Cabosun Trial Of Cabozantinib Versus Sunitinib In Previously Untreated Advanced Renal Cell Carcinoma At ESMO 2017 9/11/2017
Progression-Free Survival Data From Echo-202 Trial Of Incyte (INCY)’s Epacadostat In Combination With Keytruda (Pembrolizumab) Underscore Durability Of Response In Patients With Advanced Melanoma 9/11/2017
DelMar Pharma Initiates Phase II Clinical Trial In Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme 9/11/2017
Oncolytics Biotech (ONC.TO) Announces The Presentation Of REOLYSIN Clinical Data At ESMO 2017 Congress 9/11/2017
Ionis Pharma (IONS) Release: New Data Presented At European Society For Medical Oncology Meeting Demonstrate Antitumor Activity With IONIS-STAT3-2.5 Rx In Combination With Imfinzi 9/11/2017
electroCore Announces Results From gammaCore (Non-Invasive Vagus Nerve Stimulator) Study In Migraine At The 18th Congress Of The International Headache Society 9/11/2017
Tyme Presentation At ESMO Reported 100% Of Current Prostate Cancer Patients Have Demonstrated A Reduction In Circulating Tumor Cells, Most Becoming Undetectable 9/11/2017
Marinus Pharma (MRNS) Announces Successful Clinical Trial Results And Declares CDKL5 Disorder Its Lead Pediatric Orphan Epilepsy Program For Ganaxolone 9/11/2017
Pharming Group (PHGUF.PK) Announces Conclusion Of FDA End Of Phase II Interactions On RUCONEST For Prophylaxis Of HAE 9/11/2017
FDA Orders 6 Partial or Full Clinical Holds on Celgene (CELG)'s Blood Cancer Studies 9/8/2017
Patient Death Forces Alnylam (ALNY) to Suspend Dosing in Hemophilia Trial, Stock Plunges 9/8/2017
FDA Slaps Partial Hold on 3 of Bristol-Myers Squibb (BMY)'s Opdivo-Based Combo Trials 9/8/2017
Promius Pharma, LLC Presents Positive Results For Phase II Study Of DFN-02, A Novel Intranasal Formulation Of Sumatriptan, At 18th Congress Of The International Headache Society 9/8/2017
Updated Data For Merck & Co. (MRK)’s KEYTRUDA (Pembrolizumab) In Patients With Advanced Gastric Cancer Across Treatment Settings To Be Presented At ESMO 2017 Congress 9/8/2017
Antibe Therapeutics Announces Enrollment Of First Subjects In Phase 2B GI Safety Study For Lead Drug, ATB-346 9/8/2017
ERYtech Pharma Announces Positive Full Results From Phase IIb Study Of Eryaspase In Combination With Chemotherapy For Treatment Of Metastatic Pancreatic Cancer In Second-Line 9/8/2017
TRANSGENE (ENX:TNG) And Institut Bergonié Present A Poster On The Metromajx Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) At ESMO 2017 Congress 9/8/2017
Amgen (AMGN) Release: New Data Demonstrate Aimovig (Erenumab) Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies 9/8/2017
Immune Design Corporation (IMDZ) Release: New Randomized Data From CMB305 + Checkpoint Inhibitor Study Demonstrate Greater Clinical Benefit And Immune Response 9/8/2017
Pharmaxis (PXS.AX) Boehringer Ingelheim Is Initiating Phase Iia Study For The Development Of A New Treatment For Diabetic Retinopathy - A Leading Cause Of Vision-Loss 9/8/2017
Kura Oncology Rockets On Phase II Head And Neck Cancer Data 9/8/2017
Novartis AG (NVS) Presents New Analysis Demonstrating AMG 334 (Erenumab) Significantly Reduced Monthly Migraine Days In Patients Who Failed Previous Preventive Therapies 9/8/2017
NewLink Genetics (NLNK) Redeemed Itself After Melanoma Data Wows In Mid-Stage Study 9/8/2017
Amgen (AMGN), AstraZeneca PLC (AZN)'s Potential Asthma Blockbuster Impresses in Phase II Study 9/7/2017
AbbVie (ABBV)'s Upadacitinib (ABT-494) Meets Primary Endpoint In Phase IIb Study In Atopic Dermatitis 9/7/2017
InflaRx Reports Topline Phase IIa Clinical Results Of IFX-1 For The Treatment Of Hidradenitis Suppurativa 9/7/2017
CASI Pharma (CASI) Provides Pipeline Development Update 9/7/2017
Tyme’s Updated Long-Term Analysis Shows 29-Month Median Overall Survival In Metastatic Cancer Patients That Achieved Stable Disease 9/7/2017
Peregrine (PPHM) Announces First Patient Dosed In Phase II Clinical Trial Evaluating Bavituximab Treatment Combination In Patients With Newly Diagnosed Glioblastoma 9/7/2017
Kalytera Receives IRB Approval For Proposed Phase II Study Evaluating CBD In The Prevention Of Graft Versus Host Disease 9/7/2017
XBiotech (XBIT) Announces Presentation Of Phase II Study Data Evaluating Mabp1 For The Treatment Of Hidradenitis Suppurativa 9/7/2017
Verona Pharma (VRP.L) Announces Positive Top-Line Data From Phase IIa Clinical Trial In COPD With RPL554 Dosed In Addition To Tiotropium (Spiriva) 9/7/2017
TRACON Pharma (TCON) Announces Completion Of Enrollment In Randomized Phase IIb TRAXAR Study Of TRC105 And Inlyta® In Renal Cell Carcinoma 9/7/2017
Sanofi (SNY) Alliance Partner Alnylam (ALNY) Gives Update On Fitusiran 9/7/2017
Anergis Announces Top Line Results From Large-Scale ATIBAR Trial With Ultra-Fast Allergy Immunotherapy AllerT 9/7/2017
Medimetriks Pharmaceuticals, Inc. Announces Phase II Study Results Demonstrating Early Itch Relief For Topical PDE4 Inhibitor MM36 In Patients With Atopic Dermatitis 9/6/2017
RXi Pharma (RXII) Announces Completion Of Enrollment Of Phase II Clinical Trial With Samcyprone For Cutaneous Warts 9/6/2017
NeuroRx Awarded FDA Fast Track Designation For First Drug Regimen Targeting Suicide In Bipolar Depression 9/6/2017
Longeveron Initiates Phase IIb Stem Cell Therapy Trial To Treat Aging Frailty 9/6/2017
Allecra Release: Initiation Of A Phase 2 Clinical Trial For Its Novel Antibiotic To Treat Resistant Bacterial Infections 9/6/2017
CytoDyn (CYDY) Provides Further Update On PRO 140 Pivotal Combination Therapy Trial In Patients With HIV 9/6/2017
BioMarin (BMRN) Presents Interim Data Of Phase I/II Study Of BMN 250 For Treatment Of Sanfilippo B Syndrome (MPS IIIB) At 13th International Congress Of Inborn Errors Of Metabolism (ICIEM) 2017 9/6/2017
Dimerix Limited Announces DMX--200 Tablet Manufacture And Human Pharmacokinetic Study Timeline 9/5/2017
Eiger Biopharma Announces FDA Orphan Drug Designation Granted For Pegylated Interferon Lambda In Hepatitis Delta Virus Infection 9/5/2017
Ligand (LGND) Announces Top-Line Results From Phase II Study Of LGD-6972 In Patients With Type 2 Diabetes 9/5/2017
Acceleron Pharma Announces Publication Of Luspatercept Phase 2 Myelodysplastic Syndromes Study Results In The Lancet Oncology 9/5/2017
ReViral Initiates Phase IIa Study Of RV521 For Treatment Of Respiratory Syncytial Virus 9/5/2017
Bellerophon Therapeutics (BLPH) Announces Positive Top Line Phase II Data Of INOpulse For Treatment Of Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease 9/5/2017
Caladrius Biosciences (CLBS) Announces Enrollment Of The 70th Subject In The Phase II T-Rex Clinical Trial Of CLBS03 For Type 1 Diabetes 9/5/2017
Minerva Neurosciences (NERV) Announces Enrollment Of First Patient In Phase IIb Trial Of Seltorexant (MIN-202) As Adjunctive Therapy In Patients With Major Depressive Disorder 9/5/2017
CytoSorbents Highlights Important Research Advances In Traumatic Brain Injury, Hemorrhagic Shock, And Severe Hyperkalemia At The Military Health System Research Symposium 9/5/2017
Summit Therapeutics: Positive Top-Line Phase II Results 9/5/2017
Summit Therapeutics Announces Positive Top-Line Data From An Exploratory Phase II Clinical Trial Supporting Ridinilazole As A Highly Selective Antibiotic For The Treatment Of CDI 9/5/2017
Investors Wait with Bated Breath for AstraZeneca PLC (AZN)'s Cancer Trial Data Next Week 9/1/2017
MediWound (MDWD) Successfully Completes Second Cohort of EscharEx Phase II Study 9/1/2017
Iovance Biotherapeutics Announces FDA Fast Track Designation For LN-144 For Treatment Of Advanced Melanoma 9/1/2017
Progenics (PGNX) Presents Data From AZEDRA Pivotal Phase IIb Study At The 5th International Symposium On Pheochromocytoma And Paraganglioma 9/1/2017
Incyte (INCY) Discloses Promising New Data in Combo Drug Trial With Merck & Co. (MRK)'s Keytruda 9/1/2017
Oragenics (OGEN) Doses First Patient In Phase II Clinical Trial Of AG013 For Oral Mucositis 8/31/2017
New And Updated Data For KEYTRUDA (Pembrolizumab) From Merck & Co. (MRK)’s Extensive Immuno-Oncology Program To Be Presented At The ESMO 2017 Congress 8/31/2017
Bristol-Myers Squibb (BMY) Data At ESMO 2017 Demonstrate Company’s Innovative Research Approach To Treating Cancer From All Angles 8/31/2017
Imugene Limited (IMU.AX) Commences First Patient Dosing Of HER-Vaxx Phase Ib/II Gastric Cancer Study 8/31/2017
ERYtech Pharma To Present Full Results For Phase IIb Trial Of Eryaspase In Pancreatic Cancer At ESMO 2017 8/31/2017
Ignyta (RXDX) To Host Conference Call And Webcast On Entrectinib ROS1 Lung Cancer Update On September 6, 2017 8/31/2017
Symphogen Presents Promising Results From A Randomized Phase II Study With Sym004 At ESMO 2017 Congress 8/31/2017
Symphogen Presents Promising Results From A Randomized Phase II Study With Sym004 At ESMO 2017 Congress 8/31/2017
Immune Design Corporation (IMDZ) Announces New CMB305 + Checkpoint Inhibitor Topline Data From An Upcoming Presentation At The ESMO 2017 Congress 8/31/2017
Immune Design Corporation (IMDZ) Announces New CMB305 + Checkpoint Inhibitor Topline Data From An Upcoming Presentation At The ESMO 2017 Congress 8/31/2017
MediciNova, Inc. Announces The Abstract From The MN-166 (Ibudilast) SPRINT-MS Phase 2b Study In Progressive MS - Including Top Line Data - Was Selected As A Platform Presentation For Late-Breaking Presentation At The 7th Joint ECTRIMS - ACTRIMS Meeting On October 28, 2017 In Paris, France 8/30/2017
Tonix Pharma (TNXP) Presented Additional Phase II Clinical Results In Military-Related PTSD And Design Of Ongoing Phase III Trial At The 2017 Military Health System Research Symposium 8/30/2017
Gliknik Inc. Announces Dosing Of First Patient In Phase II Trial Targeting Prevention Of Recurrence Of High-Risk Oral Cavity Cancer 8/29/2017
Daiichi Sankyo Initiates Pivotal Phase II Study Of DS-8201 In Patients With HER2-Positive Metastatic Breast Cancer 8/29/2017
Future Unclear For Merck & Co. (MRK)'s Cholesterol Drug As Trial Data Underwhelms 8/29/2017
Probiodrug AG Release: Unique Binding Mode Of PBD-C06 To pGlu-Abeta Peptides Identified 8/29/2017
Tyme To Present Prostate Cancer Data From Its Ongoing Phase II Trial For SM-88 At ESMO 2017 8/29/2017
How A Potential Drug And A Possible M&A Could Drive Exelixis (EXEL) Even Higher 8/28/2017
GlobeImmune (GBIM) Provides Update On Recent Clinical Trial Developments 8/28/2017
GeNeuro And Servier Announce Six-Month Results From CHANGE-MS Phase IIb Study In Multiple Sclerosis 8/28/2017
Anthera Announces Top Line Final Data From The Extension Period Of The Phase II BRIGHT-SC Study Of Blisibimod In Patients With IgA Nephropathy 8/28/2017
Spring Bank Pharmaceuticals, Inc. To Present Additional Data From The First Cohort Of Its Ongoing SB 9200 ACHIEVE Clinical Trial At The 2017 International HBV Meeting In Washington D.C. 8/28/2017
Innovation Pharma (Formerly known as Cellceutix) (CTIX) Completes Full Patient Enrollment In Phase IIb Study Of Prurisol For The Oral Treatment Of Psoriasis 8/28/2017
Boehringer Ingelheim Initiates Phase IIa Study Of Compound Acquired From Pharmaxis (PXS.AX) In Debilitating Liver Disease NASH 8/25/2017
Sangamo (SGMO) And Pfizer (PFE) Announce First Patient Receives Treatment In Phase I/II Clinical Trial Evaluating SB-525 Investigational Gene Therapy For Hemophilia A 8/25/2017
Blake Insomnia Therapeutics (BKIT) Announces Submitting Clinical Trial Application For Phase II Clinical Testing 8/25/2017
Tesaro (TSRO) Announces Nine Data Presentations At The 2017 European Society For Medical Oncology (ESMO) Annual Meeting 8/25/2017
Seattle's Omeros (OMER) Fires Back But Still Won't Answer Basic Questions About Key Drug 8/24/2017
Apellis Pharma's Eye Drug Meets Primary Endpoint in Mid-Stage Study 8/24/2017
Boehringer Ingelheim Initiates Phase IIa Study Of Compound Acquired From Pharmaxis In Debilitating Liver Disease NASH 8/24/2017
Society of Urologic Oncology Release: Novel Gene Therapy Shows Three-Fold Improvement In Recurrence-Free Survival In High-Risk, Early-Stage Bladder Cancer Patients Where Current Gold-Standard Treatment Fails 8/24/2017
Enteris Biopharma Doses First Woman In Phase IIa Clinical Trial Of Ovarest (Oral Leuprolide Tablet) For Endometriosis 8/24/2017
MeiraGTx Provides Clinical Trial Updates For X-Linked Retinitis Pigmentosa And Achromatopsia Gene Therapy Programs 8/24/2017
Ultragenyx (RARE) Announces Burosumab Data Presentations At ASBMR 2017 Annual Meeting 8/24/2017
AiCuris Announces Final Patient Treated In Clinical Phase II Trial (LipP 1) With Topical Pritelivir For The Treatment Of Recurrent Labial Herpes 8/24/2017
Teikoku Pharma USA Announces Positive Topline Results From Phase II Clinical Trial Of TPU-006, Non-Opioid Pain Management Patch In Bunionectomy Surgery 8/23/2017
Lakewood-Amedex Inc. Completes Clinical Trial Recruitment For Final Cohort Of The Company's Phase I/IIa Program In Patients With Infected Diabetic Foot Ulcers 8/23/2017
Bonti Announces Start Of LANTERN-1 Phase II Clinical Study Evaluating EB-001 In Reducing Musculoskeletal Pain 8/23/2017
AtriCure (ATRC) Announces Final Patient Treated In Clinical Phase II Trial (Lipp 1) With Topical Pritelivir For The Treatment Of Recurrent Labial Herpes 8/23/2017
AzurRx BioPharma (AZRX) Reaches 6th Patient Enrollment Of Phase IIa Trial Of MS1819 For Treatment Of Exocrine Pancreatic Insufficiency Associated With Chronic Pancreatitis 8/23/2017
Symic Biomedical Enrolls First Patient In MODIFY2 Phase II Trial Of SB-061 For The Treatment Of Osteoarthritis 8/23/2017
Celldex (CLDX) Announces Completion Of Enrollment In Phase IIb Study Of Glembatumumab Vedotin In Triple Negative Breast Cancer 8/23/2017
Novogen (NVGN) Release: GDC-0084 Progress Update: On Track For Phase II Commencement In 2017 8/22/2017
Jupiter Orphan Therapeutics Receives Orphan Drug Designation For Its Trans-Resveratrol Product JOTROL For Treatment Of Friedreich's Ataxia 8/22/2017
ViraCyte Announces Positive Phase II Trial Results 8/22/2017



//-->